Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Regulatory Pathways, Trends, and News from FDA
Mary Beth Henderson, Ph.D., MBA
VP Regulatory Affairs and Quality Systems
Senior Principal Advisor
May 30 and June 01, 2017
©2017 Regulatory and Clinical Research Institute, Inc.
Agenda
Background• FDA Organization
Regulatory Pathways• Device Pathways
• Strategies to consider
Regulatory Trends and News• Greater use of De Novo Approach
• New Initiative to get products to market more quickly
• Focus on Human Factor Testing (Usability)
• Focus on Cybersecurity
Summary
©2017 Regulatory and Clinical Research Institute, Inc.
Background
©2017 Regulatory and Clinical Research Institute, Inc.
FDA Organization
©2017 Regulatory and Clinical Research Institute, Inc.
FDA Numbers: FY 2016
Pre-Submissions: 2,313
Average days to meeting: 67 (53 – 203)
Original IDE applications: 248
129 approved on first cycle
Original PMA/Panel Track Supplements: 72
180 Day Supplements: 208
Real Time Supplements: 326
510(k)s: 3,633 received/3,080 Accepted
Average calendar days to clearance: 154
De Novos: 54
©2017 Regulatory and Clinical Research Institute, Inc.
Regulatory Pathways
©2017 Regulatory and Clinical Research Institute, Inc.
Class I
Exempt
510(k) required
Class II
Exempt
510(k)
De Novo Classification
Class III
Humanitarian Use Exemption
Combination Product
Expedited Access Pathway Program
Device Classification
©2017 Regulatory and Clinical Research Institute, Inc.
•Pre-Submission
•513(g)
• Investigational Device Exemption
Other Submissions
©2017 Regulatory and Clinical Research Institute, Inc.
•Start with your indication for use• What must you have
• What is nice to have
• Identify appropriate product code(s)
• Identify predicate(s) (if available)
• Identify if there are any Special Control Documents
•Develop submission contents
Strategies
©2017 Regulatory and Clinical Research Institute, Inc.
Trends and News
©2017 Regulatory and Clinical Research Institute, Inc.
Greater use of De Novo Approach
MDUFMA 2014
Originally used almost exclusively for IVD
submissions
Went from approximately 50 de novo device
approval (total) to 50 per year
Subject of 4 recent FDA guidance documents
• Factors to consider when making benefit-risk
determinations in premarket approvals and de novo
classifications
©2017 Regulatory and Clinical Research Institute, Inc.
New Initiative
Expedited Access Program
1. Request for designation as an EAP Device (“EAP
Designation”),
2. Agreement on a Data Development Plan,
3. Review of a PMA or de novo request for an EAP
Device, and
4. If approved and appropriate, postmarket data
collection and evaluation.
©2017 Regulatory and Clinical Research Institute, Inc.
New Initiative
EAP Criteria (all of which must be met)
1. The device is intended to treat or diagnose a life-
threatening or irreversibly debilitating disease or
condition. Consider:
• Whether the device is “intended” to treat or diagnose
a life-threatening or irreversibly debilitating disease
or condition
• Whether a disease or condition is “life-threatening
• Whether a disease or condition is “irreversibly
debilitating
©2017 Regulatory and Clinical Research Institute, Inc.
New Initiatives
EAP Criteria
2. The device meets at least one of the following criteria
for addressing an unmet need:
• No appropriate alternative treatment or means of
diagnosis exists.
• The device represents a breakthrough technology that
provides a clinically meaningful advantage over existing
legally marketed technology.
• The device offers significant, clinically meaningful
advantages over existing legally marketed alternatives.
• The availability of the device is in the best interest of
patients (e.g., addresses an unmet medical need).
©2017 Regulatory and Clinical Research Institute, Inc.
New Initiatives
EAP Criteria
3. The sponsor submits an acceptable draft Data
Development Plan
©2017 Regulatory and Clinical Research Institute, Inc.
Focus: Human Factors
Original guidance issued in 1997
Four Guidance Documents issued March 2016:• Comparative Analyses and Related Comparative Use Human
Factors Studies for a Drug-Device combination Product
Submitted in an ANDA
• Applying Human Factors and Usability Engineering to Medical
devices
• Human Factors Studies and Related Clinical Study
Considerations in Combination Product Design and
Development
• List of Highest Priority Devices for Human Factors Review
©2017 Regulatory and Clinical Research Institute, Inc.
Focus: Human Factors Testing
• Help to ensure device safety and effectiveness
• Reduce risk by reducing design flaws/use errors
prior to design lock
• Key component of best practice in design control
• Consider
Device users
Device use environment
Device/User Interface
©2017 Regulatory and Clinical Research Institute, Inc.
Focus: Cybersecurity
Dec 2016
• Postmarket Management of Cybersecurity in Medical
Devices
Oct 2014
• Content of Premarket Submissions for Management of
Cybersecurity in Medical Devices
Feb 2005
• Information for Healthcare Organization about FDA’s
Guidance for Industry: Cybersecurity for Networked Medical
Devices Containing OTS Software
Jan 2005
• Guidance for Industry—Cybersecurity for Networked Medical
Devices Contains OTC Software
©2017 Regulatory and Clinical Research Institute, Inc.
Focus: Cybersecurity
Implement a proactive, comprehensive risk management
program
• Apply the National Institute of Standards and Technology
(NIST) Framework to Strengthen Critical Infrastructure
Cybersecurity
• Establish and communicate processes for vulnerability intake
and handling
• Adopt a coordinated disclosure policy and practice
• Deploy mitigations that address cybersecurity risk early and
prior to exploitation
• Engage in collaborative information sharing for cyber
vulnerabilities and threats
FDA Webinar 17 Jan 21017
©2017 Regulatory and Clinical Research Institute, Inc.
Summary
©2017 Regulatory and Clinical Research Institute, Inc.
Summary
• Regulatory pathway is determined by your
intended use (claims)
• Your regulatory pathway needs to integrate with
your evidence development and reimbursement
strategy
• Pre-submissions are an excellent method of
obtaining FDA feedback (i.e., prior to
animal/human clinical testing)
• Any device with software is being reviewed more
rigorously
Mary Beth Henderson, Ph.D., MBA
Vice President Regulatory Affairs & Quality Systems, Sr. Principal Advisor
Regulatory and Clinical Research Institute, Inc. (RCRI)
5353 Wayzata Blvd. Suite 505, Minneapolis, MN 55416
Direct: 952-595-5580 Cell: 612-8399138
[email protected] www.rcri-inc.com
Questions